A CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TUKHM-I KAHU IN THE MANAGEMENT OF ZAGHT AL-DAM QAWĪLĀZIMĪ (ESSENTIAL HYPERTENSION)

Zareena Aquil, Qamar Uddin, M. H. Kazmi, W. Ahmad
{"title":"A CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TUKHM-I KAHU IN THE MANAGEMENT OF ZAGHT AL-DAM QAWĪLĀZIMĪ (ESSENTIAL HYPERTENSION)","authors":"Zareena Aquil, Qamar Uddin, M. H. Kazmi, W. Ahmad","doi":"10.7897/2321-6328.075112","DOIUrl":null,"url":null,"abstract":"Aim of this study is to assess the efficacy of Tukhm-ikahu in Zaght al-Dam Qawī Lāzimī (Essential Hypertension) in comparison to Amlodipine (5 mg) tablet. Randomized, standard controlled clinical study was carried out. Patients of high blood pressure (n = 60) with age 35 to 55 years, with Stage-I Hypertension according to JNC 7 (Systolic BP 140-159 and Diastolic BP 90-99 mmHg) were randomized into study; tukhm-ikahu and control; amlodipine (5 mg) groups by block randomization method. Patients with SBP ≥ 160 mmHg and DBP ≥ 100 mmHg, Secondary Hypertension, Pregnant and Lactating women, Obese subjects – BMI > 30, Drug Addicts and Alcoholics were excluded from the study. Study group patients were given 5 gm of powder of tukhm-ikahu twice daily and those of control group Amlodipine 5 mg once daily. Duration of treatment was 6 weeks. Significant difference between Tukhm-ikahu and amlodipine was observed regarding improvement in headache (86.7% vs. 60%), Pvalue 0.039, vertigo (93.3% vs. 66.7%), Pvalue 0.021 and sleeplessness (96.67% vs. 73.3%), Pvalue 0.010. No significant difference was observed between the two regarding reduction in systolic and diastolic pressure at end point of study (Pvalue 0.675 and 0.552 respectively). No significant difference between the two was recorded regarding palpitation, laziness, anxiety, breathlessness, pulse rate, respiratory rate and temperature; P-value 0.080, 0.299, 0.748, 0.960, 0.858, 0.858 and 0.233 respectively. Tukhm-ikahu possesses efficiency and potency towards treating the high blood pressure and managing the symptoms linked with it.","PeriodicalId":118022,"journal":{"name":"Journal of Biological & Scientific Opinion","volume":"47 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biological & Scientific Opinion","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7897/2321-6328.075112","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim of this study is to assess the efficacy of Tukhm-ikahu in Zaght al-Dam Qawī Lāzimī (Essential Hypertension) in comparison to Amlodipine (5 mg) tablet. Randomized, standard controlled clinical study was carried out. Patients of high blood pressure (n = 60) with age 35 to 55 years, with Stage-I Hypertension according to JNC 7 (Systolic BP 140-159 and Diastolic BP 90-99 mmHg) were randomized into study; tukhm-ikahu and control; amlodipine (5 mg) groups by block randomization method. Patients with SBP ≥ 160 mmHg and DBP ≥ 100 mmHg, Secondary Hypertension, Pregnant and Lactating women, Obese subjects – BMI > 30, Drug Addicts and Alcoholics were excluded from the study. Study group patients were given 5 gm of powder of tukhm-ikahu twice daily and those of control group Amlodipine 5 mg once daily. Duration of treatment was 6 weeks. Significant difference between Tukhm-ikahu and amlodipine was observed regarding improvement in headache (86.7% vs. 60%), Pvalue 0.039, vertigo (93.3% vs. 66.7%), Pvalue 0.021 and sleeplessness (96.67% vs. 73.3%), Pvalue 0.010. No significant difference was observed between the two regarding reduction in systolic and diastolic pressure at end point of study (Pvalue 0.675 and 0.552 respectively). No significant difference between the two was recorded regarding palpitation, laziness, anxiety, breathlessness, pulse rate, respiratory rate and temperature; P-value 0.080, 0.299, 0.748, 0.960, 0.858, 0.858 and 0.233 respectively. Tukhm-ikahu possesses efficiency and potency towards treating the high blood pressure and managing the symptoms linked with it.
tukhm-i kahu治疗原发性高血压qawĪlĀzimĪ疗效和安全性的临床研究
本研究的目的是评估Tukhm-ikahu与氨氯地平(5 mg)片相比对Zaght al-Dam qawir Lāzimī(原发性高血压)的疗效。进行随机、标准对照临床研究。根据JNC 7(收缩压140-159和舒张压90-99 mmHg),年龄35 - 55岁的i期高血压患者(n = 60)被随机纳入研究;Tukhm-ikahu和控制;氨氯地平(5mg)组采用分组随机法。排除收缩压≥160 mmHg和舒张压≥100 mmHg的患者、继发高血压、孕妇和哺乳期妇女、肥胖受试者- BMI > 30、吸毒成瘾者和酗酒者。对照组患者给予氨氯地平5 mg,每日1次。治疗时间为6周。Tukhm-ikahu与氨氯地平在改善头痛(86.7% vs. 60%)、眩晕(93.3% vs. 66.7%)、失眠(96.67% vs. 73.3%)、p值0.010方面差异有统计学意义。在研究结束时,两组在收缩压和舒张压降低方面无显著差异(p值分别为0.675和0.552)。两组在心悸、懒惰、焦虑、呼吸困难、脉搏率、呼吸率和体温方面没有显著差异;p值分别为0.080、0.299、0.748、0.960、0.858、0.858、0.233。Tukhm-ikahu在治疗高血压和控制与高血压有关的症状方面具有效率和效力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信